Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation
Jeffrey L. Cummings, Jefferson W. Kinney
Medicina (2022) Vol. 58, Iss. 7, pp. 952-952
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Alzheimer's disease drug development pipeline: 2023
Jeffrey L. Cummings, Yadi Zhou, Garam Lee, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 321
Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
Zdeněk Fišar
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1676-1676
Open Access | Times Cited: 52
The potential clinical value of plasma biomarkers in Alzheimer's disease
Kaj Blennow, Douglas Galasko, Robert Perneczky, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 12, pp. 5805-5816
Open Access | Times Cited: 35
The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer’s Disease-like Mouse Model
Juyong Kim, Pilju Choi, Young‐Tae Park, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6827-6827
Open Access | Times Cited: 27
Plasma biomarkers for Alzheimer’s and related dementias: A review and outlook for clinical neuropsychology
Heather E. Dark, Michael R. Duggan, Keenan A. Walker
Archives of Clinical Neuropsychology (2024) Vol. 39, Iss. 3, pp. 313-324
Open Access | Times Cited: 14
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Michael Schöll, Inge M.W. Verberk, Marta del Campo, et al.
The Lancet Healthy Longevity (2024) Vol. 5, Iss. 10, pp. 100630-100630
Open Access | Times Cited: 12
Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer’s disease pathology
Anuschka Silva‐Spínola, Maria João Leitão, Alícia Nadal, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
The therapeutic landscape of tauopathies: challenges and prospects
Jeffrey L. Cummings, María Isabel González, Martyn C. Pritchard, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 21
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
Amanda M. Leisgang Osse, Jefferson W. Kinney, Jeffrey L. Cummings
Alzheimer s & Dementia Translational Research & Clinical Interventions (2025) Vol. 11, Iss. 1
Open Access
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Antoine Leuzy, Ariane Bollack, Daniela Pellegrino, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access
Neuroprotective Effects of Dendrobium nobile
Surendra Sarsaiya, Archana Jain, Qihai Gong, et al.
CABI eBooks (2025), pp. 198-217
Closed Access
Biomarkers for clinical use in psychiatry: where are we and will we ever get there?
Lakshmi N. Yatham
World Psychiatry (2023) Vol. 22, Iss. 2, pp. 263-264
Open Access | Times Cited: 11
Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications
Sarrah E Ankeny, Julia R Bacci, Boris Decourt, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 6, pp. 1541-1557
Open Access | Times Cited: 4
Insights into the use of biomarkers in clinical trials in Alzheimer's disease
Tharick A. Pascoal, Cristiano Schaffer Aguzzoli, Firoza Z Lussier, et al.
EBioMedicine (2024), pp. 105322-105322
Open Access | Times Cited: 4
Best Medicine for Dementia: The Life-Long Defense of the Brain
Marcus J. Andersson, Jonathan Stone
Journal of Alzheimer s Disease (2023) Vol. 94, Iss. 1, pp. 51-66
Closed Access | Times Cited: 9
Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer’s Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers
Joachim Strobel, Elham Yousefzadeh-Nowshahr, Katharina Deininger, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1460-1460
Open Access | Times Cited: 3
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease
Aurore Delvenne, Johan Gobom, Suzanne E. Schindler, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6205-6220
Open Access | Times Cited: 3
An inclusive study of recent advancements in Alzheimer's disease: A comprehensive review
Sukanya Singh, Mitali Mahajan, D. Renjith Kumar, et al.
Neuropeptides (2023) Vol. 102, pp. 102369-102369
Closed Access | Times Cited: 7
Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Jana Hroudová, Zdeněk Fišar
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111069-111069
Closed Access | Times Cited: 2
Moving Towards Ethical-Practical Recommendations for Alzheimer’s Disease Prediction: Addressing Interindividual, Interprofessional, and Societal Aspects
Silke Schicktanz, Zümrüt Alpinar-Segawa, Natalie Ulitsa, et al.
Journal of Alzheimer s Disease (2024), pp. 1-19
Closed Access | Times Cited: 2
Geroscience and Alzheimer’s Disease Drug Development
Jeffrey L. Cummings, Amanda M. Leisgang Osse, J. M. Kinney
The Journal of Prevention of Alzheimer s Disease (2023)
Open Access | Times Cited: 6
The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging
Meriel Owen, Nandita Bose, Laura Nisenbaum, et al.
The Journal of Prevention of Alzheimer s Disease (2023)
Open Access | Times Cited: 6
Contextualizing the Role of Osteopontin in the Inflammatory Responses of Alzheimer’s Disease
Roshni C. Lalwani, Claude‐Henry Volmar, Claes Wahlestedt, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3232-3232
Open Access | Times Cited: 6
Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectives
Jiangwei Zhang, Sarah N. Campion, Natasha R. Catlin, et al.
Archives of Toxicology (2023) Vol. 97, Iss. 4, pp. 947-961
Open Access | Times Cited: 5
A PAM of the α1A-Adrenergic receptor rescues biomarker, long-term potentiation, and cognitive deficits in Alzheimer’s disease mouse models without effects on blood pressure
Robert S. Papay, Shaun R. Stauffer, Dianne M. Perez
Current Research in Pharmacology and Drug Discovery (2023) Vol. 5, pp. 100160-100160
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top